Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background Increasing the available repertoire of effective treatments for mood and anxiety disorders represents a critical unmet need. Pharmacological augmentation of endogenous cannabinoid (eCB) signaling has been suggested to represent a novel approach to the treatment of anxiety disorders; however, the functional interactions between two canonical eCB pathways mediated via anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in the regulation of anxiety are not well understood. Methods We utilized pharmacological augmentation and depletion combined with behavioral and electrophysiological approaches to probe the role of 2-AG signaling in the modulation of stress-induced anxiety, and the functional redundancy between AEA and 2-AG signaling in the modulation of anxiety-like behaviors in mice. Results Selective 2-AG augmentation reduced anxiety in the light-dark box assay, and prevented stress-induced increases in anxiety associated with limbic AEA deficiency. In contrast, acute 2-AG depletion increased anxiety-like behaviors, which was normalized by selective pharmacological augmentation of AEA signaling and via direct CB1 receptor stimulation with tetrahydrocannabinol (THC). Electrophysiological studies revealed 2-AG modulation of amygdala glutamatergic transmission as a key synaptic correlate of the anxiolytic effects of 2-AG augmentation. Conclusions Although AEA and 2-AG likely subserve distinct physiological roles, a pharmacological and functional redundancy between these canonical eCB signaling pathways exists in the modulation of anxiety-like behaviors. These data support development of eCB-based treatment approaches for mood and anxiety disorders and suggest a potentially wider therapeutic overlap between AEA and 2-AG augmentation approaches than previously appreciated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“The endogenous cannabinoid (eCB) system is a retrograde lipid signaling system that is implicated in the regulation of multiple physiological functions in the nervous system (7, 8).”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Mood disorders and allostatic load
McEwen, B. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00177-x · Cited by 1,135
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475
Self-citationBenzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.03.013 · Cited by 328
Patel, S., Roelke, C. T., Rademacher, D. J., & Hillard, C. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03916.x · Cited by 297 · cited 1×
“We and others have also previously shown that stress and high levels of emotional arousal reduced AEA levels [(31, 39, 45, 48, 49), and current data], especially in the amygdala, and that AEA levels are inversely correlated with anxiety-like behaviors (16, 25, 50) as well as with stress induced corticosterone secretio…”
BackgroundSelf-citationDifferential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.08.004 · Cited by 256 · cited 2×
“2-AG is the most abundant eCB in the brain and clinical studies have demonstrated reduced peripheral 2-AG levels in patients with PTSD and with major depression (24, 25).”
BackgroundAcute stress increases circulating anandamide and other N-acylethanolamines in healthy humans
Dlugos, A., Childs, E., Stuhr, K. L., Hillard, C. J., & de Wit, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.100 · Cited by 248 · cited 1×
“We and others have also previously shown that stress and high levels of emotional arousal reduced AEA levels [(31, 39, 45, 48, 49), and current data], especially in the amygdala, and that AEA levels are inversely correlated with anxiety-like behaviors (16, 25, 50) as well as with stress induced corticosterone secretio…”
BackgroundCorticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety
Gray, J. M., Vecchiarelli, H. A., Morena, M., Lee, T. T. Y., Hermanson, D. J., Kim, A. B., McLaughlin, R. J., Hassan, K. I., Kühne, C., Wotjak, C. T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2737-14.2015 · Cited by 246
Self-citationRademacher, D. J., Meier, S. E., Shi, L., Vanessa Ho, W.-S., Jarrahian, A., & Hillard, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.012 · Cited by 233 · cited 1×
“We and others have also previously shown that stress and high levels of emotional arousal reduced AEA levels [(31, 39, 45, 48, 49), and current data], especially in the amygdala, and that AEA levels are inversely correlated with anxiety-like behaviors (16, 25, 50) as well as with stress induced corticosterone secretio…”
BackgroundAmygdala FAAH and anandamide: mediating protection and recovery from stress
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., & Holmes, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.008 · Cited by 229 · cited 2×
“Combined with a large volume of data implicating increased amygdala activity in generating fear and anxiety-like responses (18, 20, 52, 53), increases in sEPSC are suggested to be causally related to the observed anxiety-like phenotype observed after stress exposure.”
BackgroundHill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., Cravatt, B. F., Hillard, C. J., Chattarji, S., & McEwen, B. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.90 · Cited by 222 · cited 1×
“Combined with a large volume of data implicating increased amygdala activity in generating fear and anxiety-like responses (18, 20, 52, 53), increases in sEPSC are suggested to be causally related to the observed anxiety-like phenotype observed after stress exposure.”
BackgroundSciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179 · cited 1×
“Previous studies have provided mixed results in this regard; while Busques-Garcia found the anxiolytic effects of MAGL inhibition were mediated by CB2 (28) but not CB1 receptors, Lim et al, Morena et al, Sciolino et al, and the present results clearly indicate a CB1-mediated mechanism (29, 30, 43).”
ResultKinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
Anxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169
Patel, S., & Hillard, C. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06266.x · Cited by 162 · cited 1×
“In contrast to AEA, stress generally increases 2-AG levels (32), which contributes to termination and adaptation to stress, as well as potentially contributing to changes in pain perception and emotional memory (13, 33).”
BackgroundSelf-citationBluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157 · cited 2×
“For example, stress exposure reduces amygdala AEA levels, and reductions in AEA levels after stress correlate with anxiety-like behavioral states (16, 31).”
BackgroundSelf-citationShonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
Hermanson, D. J., Hartley, N. D., Gamble-George, J., Brown, N., Shonesy, B. C., Kingsley, P. J., Colbran, R. J., Reese, J., Marnett, L. J., & Patel, S. (2013) · Nature Neuroscience · doi:10.1038/nn.3480 · Cited by 126
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00005 · Cited by 80
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Aliczki, M., Zelena, D., Mikics, E., Varga, Z. K., Pinter, O., Bakos, N. V., Varga, J., & Haller, J. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.03.017 · Cited by 50
Cited by
Liu, Q.-R., Canseco-Alba, A., Zhang, H.-Y., Tagliaferro, P., Chung, M., Dennis, E., Sanabria, B., Schanz, N., Escosteguy-Neto, J. C., Ishiguro, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17796-y · Cited by 147
Endocannabinoid Signaling Collapse Mediates Stress-Induced Amygdalo-Cortical Strengthening
Marcus, D. J., Bedse, G., Gaulden, A. D., Ryan, J. D., Kondev, V., Winters, N. D., Rosas-Vidal, L. E., Altemus, M., Mackie, K., Lee, F. S., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.024 · Cited by 104
“Conversely, 2-AG augmentation promotes stress resilience and prevents stress-induced anxiety (Bedse et al., 2017; Bluett et al., 2017; Bosch-Bouju et al., 2016; McLaughlin et al., 2014; Patel et al., 2009; Qin et al., 2015; Sciolino et al., 2011; Sumislawski et al., 2011).”
Self-citationCannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms
DeVuono, M. V., & Parker, L. A. (2020) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0059 · Cited by 87
Serrano, A., Pavon, F. J., Buczynski, M. W., Schlosburg, J., Natividad, L. A., Polis, I. Y., Stouffer, D. G., Zorrilla, E. P., Roberto, M., Cravatt, B. F., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0055-3 · Cited by 83
Lisboa, S. F., Vila-Verde, C., Rosa, J., Uliana, D. L., Stern, C. A. J., Bertoglio, L. J., Resstel, L. B., & Guimaraes, F. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5127-x · Cited by 54
Metadata
- Authors
- Bedse, G., Hartley, N. D., Neale, E., Gaulden, A. D., Patrick, T. A., Kingsley, P. J., Uddin, M. J., Plath, N., Marnett, L. J., & Patel, S.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 82
- Issue
- 7
- Pages
- 488-499
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2601763229
- Cited by
- 106
- References
- 26
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.